Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Neurological Sciences
Published in: Neurological Sciences 1/2018

01-06-2018 | MANAGEMENT AND THERAPY

OnabotulinumtoxinA for chronic migraine: a real-life Italian multicenter experience

Authors: Fabrizio Vernieri, Matteo Paolucci, Claudia Altamura, Patrizio Pasqualetti, Vincenzo Mastrangelo, Giulia Pierangeli, Sabina Cevoli, Domenico D’Amico, Licia Grazzi

Published in: Neurological Sciences | Special Issue 1/2018

Login to get access

Excerpt

Chronic migraine (CM) is a disabling neurological disorder affecting about 2% of the population [1]. It occurs on 15 or more days per month for more than 3 months, having the features of migraine headache on at least 8 days per month. People with CM have impaired quality of life, more severe disability, and greater economic burden than patients with episodic migraine (EM). Furthermore, patients with CM are often poor responders to prophylactic treatments. …
Literature
1.
Bigal ME, Serrano D, Reed M, Lipton RB (2008) Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 71:559–566CrossRef
2.
Aurora SK, Dodick DW, Turkel CC, RE DG, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT 1 Chronic Migraine Study Group (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30:793–803CrossRef
3.
Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF, PREEMPT 2 Chronic Migraine Study Group (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30:804–814CrossRef
Metadata
Title
OnabotulinumtoxinA for chronic migraine: a real-life Italian multicenter experience
Authors
Fabrizio Vernieri
Matteo Paolucci
Claudia Altamura
Patrizio Pasqualetti
Vincenzo Mastrangelo
Giulia Pierangeli
Sabina Cevoli
Domenico D’Amico
Licia Grazzi
Publication date
01-06-2018
Publisher
Springer International Publishing
Published in
Neurological Sciences / Issue Special Issue 1/2018
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-018-3393-3

Other articles of this Special Issue 1/2018

Neurological Sciences 1/2018 Go to the issue

Review Article

What the pharmacological management of migraine can tell us about the future of migraine patient care

MANAGEMENT AND THERAPY

Relationship between severity of migraine and vitamin D deficiency: a case-control study

PEDIATRIC HEADACHE

How to treat children with headache

MIGRAINE PATHOGENESIS

What have we learned from genetic of migraine?

SYMPTOMATIC HEADACHES OF THE CRANIO-FACIAL DISTRICT

The possible influence of foramen ovale and obstructive sleep apnoeas on trigeminal autonomic cephalalgias: preliminary results of a ANIRCEF-PROGRAN study

SYMPTOMATIC HEADACHES OF THE CRANIO-FACIAL DISTRICT

Bipolar disorder and chronic migraine: an open problem